Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade
Key Points
Polovin executed the sale of 30,075 shares between August 18 and August 19, generating approximately $1.5 million in proceeds.
The transaction was non-discretionary and performed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.
Post-transaction, the insider maintains a direct position of about 138,000 shares, reflecting continued long-term exposure to the firm.
- 10 stocks we like better than Tempus AI ›
Andrew Polovin, the firm's EVP and chief legal officer, sold 30,075 shares of Tempus AI, Inc. (NASDAQ:TEM) at $51.29 per share in a transaction totaling $1.5 million, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $1.5 million |
| Shares sold | 30,075 |
| Post-transaction shares (directly held) | 138,140 |
| Post-transaction value | $8.5 million |
Transaction value based on SEC Form 4 weighted average sale price ($51.29); post-transaction value based on the August 19 market close ($61.25).
Key questions
- What was the primary driver for this share disposition?
The transaction was non-discretionary, executed to cover minimum statutory tax withholding obligations tied to the vesting of restricted stock units, and does not reflect the insider's discretionary view on the stock. - How significant is the remaining equity stake?
Following the disposition, Polovin retains 138,140 shares with an estimated market value of $8.5 million as of the August 19 close. - Does this transaction follow a pre-established strategy?
The sale was conducted under a Rule 10b5-1 trading plan established on August 12, 2025, which provides for systematic liquidity while ensuring compliance with securities regulations regarding material non-public information.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-19) | $61.25 |
| Market Capitalization | $10.7 billion |
| Revenue (TTM) | $1.4 billion |
| Net Income (TTM) | -$254.4 million |
Company Snapshot
- Tempus AI operates a closed-loop healthcare technology platform that integrates clinician workflows with laboratory diagnostic capabilities, analytics, and multimodal data repositories, generating revenue through its Tempus platform and Hub clinical application for next-generation sequencing (NGS) testing.
- The company operates a software-as-a-service and diagnostic services business model, monetizing through platform subscriptions, clinical application licensing, and laboratory testing services delivered to healthcare providers and medical institutions.
- Tempus AI primarily serves physicians, healthcare providers, and clinical laboratories seeking advanced diagnostic capabilities and data-driven clinical decision support tools for oncology and precision medicine applications.
Tempus AI is a healthcare technology company headquartered in Chicago, with a $10.7 billion market capitalization and 3,800 employees. The company has established a vertically integrated platform combining clinical software, diagnostic analytics, and laboratory services to address the precision medicine market, though it remains unprofitable on a TTM basis with negative net income of $254.4 million as it invests in platform expansion and market penetration.
What this transaction means for investors
Polovin's sale is a routine sell-to-cover on a 10b5-1 plan he set up back in August 2025, executing on schedule the same week Tempus stock happened to explode, which says nothing about his read on the company.
The more useful question, and the one investors should be watching for, is whether Tempus is worth buying after the swing it just had. The stock is down roughly 10% over the past year, but it's rallied about 75% since late last month, and even after that run, it's still sitting something like 30% below its all-time high near $104. Notably, the staggering run higher this past week wasn't driven by anything Tempus itself announced. It came from a Moderna and Merck cancer vaccine trial hitting its endpoints, which validates the genomic sequencing technology behind Tempus's pending $1.5 billion Personalis deal. The business backed that up with real numbers too, revenue up 22% to $382.5 million last quarter and its first GAAP profit, a quarter CEO Eric Lefkofsky called "another exceptional quarter for us." Whether that combination justifies the current price, or whether the rally has already priced in more than one trial readout confirms, is the real debate here rather than Polovin's tax bill.
Should you buy stock in Tempus AI right now?
Before you buy stock in Tempus AI, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus AI wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $432,189!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,330,956!*
Now, it’s worth noting Stock Advisor’s total average return is 967% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 22, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tempus AI. The Motley Fool has a disclosure policy.
Recommended Articles
